Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENICILLAMINE vs CUPRIMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Lead poisoning,Mercury poisoning,Arsenic poisoning
Wilson disease,Cystinuria,Rheumatoid arthritis (off-label)
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Hepatic metabolism to S-methyl-penicillamine and penicillamine disulfide; also undergoes renal excretion.
Metabolized by oxidation and reduction; primarily renal elimination.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Renal: ~80% as unchanged drug, biliary/fecal: <5%
~80% bound to plasma proteins, primarily albumin.
~70% bound, primarily to serum albumin.
Vd: 0.1–0.2 L/kg; indicates distribution mainly in extracellular fluid and limited tissue penetration, though accumulates in skin and connective tissue.
Vd: 0.5–1.0 L/kg (approximately 70 L in adults). Indicates distribution into total body water with moderate tissue binding.
Oral: 40–70% (variable due to food and metal ions).
Oral: Approximately 40–70% (variable, reduced by food, especially high-protein meals; administration on empty stomach recommended).
Cr Cl >=50 m L/min: no adjustment; Cr Cl 30-49 m L/min: reduce dose by 50%; Cr Cl 10-29 m L/min: reduce dose by 75%; Cr Cl <10 m L/min: avoid use.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 25-50%. Monitor urinary copper and adjust accordingly.
No specific adjustments recommended; use with caution in severe hepatic impairment.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to hepatotoxicity risk. Monitor liver function.
For Wilson disease: 250 mg/m²/day orally in divided doses; for cystinuria: 30 mg/kg/day in divided doses; for rheumatoid arthritis: 2.5-5 mg/kg/day, titrated slowly.
10-20 mg/kg/day orally divided into 2-4 doses; typical starting dose 15 mg/kg/day for Wilson disease (max 1 g/day). Titrate based on urinary copper.
Initiate at low end of dosing range; monitor renal function closely; increased risk of hematologic and autoimmune adverse effects.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal decline; monitor renal function and copper levels.
None explicitly issued by FDA.
WARNING: CUPRIMINE can cause severe bone marrow depression leading to aplastic anemia, leukopenia, thrombocytopenia, and agranulocytosis. Deaths have occurred. Monitor blood counts closely.
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia), proteinuria/nephrotic syndrome, autoimmune reactions (myasthenia gravis, Goodpasture's syndrome, lupus-like syndrome), severe skin reactions (toxic epidermal necrolysis), hepatotoxicity, cross-allergenicity with penicillin. Requires monitoring of CBC, urinalysis, liver function.
Bone marrow suppression, renal toxicity (proteinuria, hematuria), lupus-like syndrome, myasthenia gravis-like syndrome, rash, and hypersensitivity reactions. Monitor renal function, blood counts, and urinalysis regularly.
History of aplastic anemia or agranulocytosis, severe renal insufficiency, pregnancy (especially first trimester), breastfeeding, hypersensitivity to penicillamine or penicillin.
History of penicillamine-related aplastic anemia or agranulocytosis; concurrent gold therapy, antimalarial drugs, or immunosuppressants; rheumatoid arthritis patients with renal insufficiency.
Avoid high-protein meals and dairy products around dosing; they decrease penicillamine absorption. Separate intake from iron supplements, antacids, and zinc by at least 2 hours. For cystinuria, maintain high fluid intake and possibly restrict sodium and methionine-rich foods (e.g., meats, dairy) as part of therapy.
Take on an empty stomach. Avoid food, especially milk, and any mineral supplements (iron, zinc, calcium) for at least 1 hour before and 2 hours after dosing, as they reduce absorption. Alcohol should be avoided due to potential hepatotoxicity.
First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or cystinuria. Second/third trimesters: Risk of fetal connective tissue defects; avoid unless essential.
First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential for growth restriction. Third trimester: Risk of fetal copper deficiency and associated neurological impairment. Pregnancy category D.
Excreted in breast milk; M/P ratio approximately 0.1. Low concentrations are present; however, due to potential adverse effects (e.g., rash, bone marrow suppression), caution is advised. Consider monitoring infant for rash or blood dyscrasias.
Excreted in breast milk. M/P ratio not established. Contraindicated in breastfeeding due to potential for severe adverse effects (hypersensitivity, bone marrow suppression) in the infant.
No specific dose adjustment is recommended based on pharmacokinetic changes alone; however, due to potential teratogenicity, use only when necessary. Therapeutic drug monitoring may be considered to ensure efficacy without excessive toxicity.
No standard dose adjustment recommended; use lowest effective dose. Monitor serum copper to maintain therapeutic levels due to altered pharmacokinetics in pregnancy (increased volume of distribution, renal clearance).
Penicillamine is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for bone marrow suppression, proteinuria, and autoimmune reactions. Administer on an empty stomach (1 hour before or 2 hours after meals). Avoid concurrent use with gold, antimalarials, or immunosuppressants due to increased toxicity. Discontinue if rash, fever, or lymphadenopathy develop.
Monitor for proteinuria and hematuria; perform urinalysis weekly initially, then monthly. Penicillamine can cause bone marrow suppression; obtain baseline CBC and differential, then monitor every 2 weeks for first 6 months, then monthly. Drug-induced lupus and myasthenia gravis are rare but serious autoimmune adverse effects. Avoid in patients with a history of penicillin allergy due to potential cross-sensitivity. Administer on an empty stomach at least 1 hour before or 2 hours after meals to enhance absorption. Dose adjustments needed in renal impairment. Pyridoxine (vitamin B6) supplementation (25-50 mg/day) is recommended to prevent deficiency caused by penicillamine. For Wilson disease, monitor 24-hour urinary copper excretion to guide therapy.
Take penicillamine on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid taking with milk, antacids, or iron supplements as they reduce absorption.,Report any unexplained bruising, bleeding, sore throat, or fever immediately.,Watch for signs of proteinuria (foamy urine) or hematuria (blood in urine).,Do not stop abruptly; dose tapering is required.,Use effective contraception; penicillamine can cause fetal harm.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not skip doses; take exactly as prescribed and do not double up if a dose is missed.,Report any signs of allergy promptly: rash, itching, fever, joint pain, or swollen lymph nodes.,Contact your doctor immediately if you experience easy bruising, bleeding, or signs of infection such as fever or sore throat.,Inform your doctor about any planned vaccinations; avoid live vaccines while on this medication.,You may need regular blood and urine tests to monitor for side effects.,If you are taking iron supplements or other mineral supplements, take them at least 2 hours apart from this medication to prevent reduced absorption.,Use effective contraception if you are of childbearing age; this drug can harm an unborn baby.,Avoid alcohol as it may increase the risk of liver toxicity.,Notify your dentist about your medication history before any dental procedures.
"Almasilate, an aluminum-containing antacid, can adsorb penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This leads to decreased serum concentrations of penicillamine, potentially diminishing its therapeutic effect in diseases such as rheumatoid arthritis or Wilson's disease. Clinically, this interaction may result in loss of disease control or require dose adjustments."
"Calcium carbonate, a common antacid and calcium supplement, chelates with penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This interaction significantly decreases the bioavailability and serum concentration of penicillamine, potentially compromising its therapeutic efficacy in treating conditions such as rheumatoid arthritis or Wilson's disease. Clinical outcomes may include loss of disease control or increased disease activity, particularly if the drugs are taken concomitantly."
"Concomitant administration of penicillamine and teriflunomide may significantly increase the serum concentration of teriflunomide, primarily due to penicillamine's inhibition of the organic anion transporter 3 (OAT3)-mediated renal elimination of teriflunomide. Elevated teriflunomide levels heighten the risk of dose-dependent adverse effects, including hepatotoxicity, peripheral neuropathy, and immunosuppression. This interaction warrants careful monitoring and potential dose adjustment to avoid toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENICILLAMINE vs CUPRIMINE, answered by our medical review team.
PENICILLAMINE is a Chelating Agent that works by Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.. CUPRIMINE is a Chelating Agent that works by Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENICILLAMINE and CUPRIMINE depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENICILLAMINE is: 250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.. The standard adult dose of CUPRIMINE is: 250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENICILLAMINE and CUPRIMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENICILLAMINE is classified as Category C. First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or c. CUPRIMINE is classified as Category C. First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.